International Clinical Trial: A multicenter, open-label, randomized controlled clinical study evaluating the efficacy of anlotinib combined with temozolomide in the treatment of first recurrent high-grade glioma

Geneva, July 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127167) titled 'A multicenter, open-label, randomized controlled clinical study evaluating the efficacy of anlotinib combined with temozolomide in the treatment of first recurrent high-grade glioma' on June 25.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: The First Affiliated Hospital of Army Medical University

Condition: Glioma

Intervention: experimental group:Anlotinib combined with Temozolomide Anlotinib: 10-12 mg/day orally on days 1-14, followed by a 7?day rest (days 15-21), with a 3?week cycle. Temozolomide: administered according to the postoperative Stupp regimen, 5 days on / 23 days off...